Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Farxiga

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in US

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

Antithrombotic Therapy for Peripheral Artery Disease: Medscape Education and Outcomes

At this year’s ACC2023 event, the Medscape Education team shared 7 posters highlighting the outcomes of cardiology continuing medical education (CME) programs. These posters covered a variety of cardiology topics...

Medscape Education Global

- PMLiVE

AstraZeneca presents positive phase 3 results for Imfinzi regimen in lung cancer

Around 2.2 million people are diagnosed with lung cancer globally each year

- PMLiVE

AstraZeneca’s Lynparza recommended by NICE for breast and prostate cancer

An estimated 800 patients will now be eligible for treatment with the drug

- PMLiVE

AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma

An estimated 98,000 patients with severe uncontrolled asthma may be eligible for the new treatment

- PMLiVE

AstraZeneca’s mild combination asthma reliever approved in UK

Over two and a half million adults with mild cases of asthma could be eligible for the treatment

- PMLiVE

AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer

More than 52,000 men are diagnosed with prostate cancer every year in the UK alone

- PMLiVE

Medscape Education Demonstrates Deep Cardiology Outcomes Expertise at ACC 2023

As cardiologists from around the world return home from New Orleans and ACC 2023, Medscape Education is looking back at a successful conference.At this year’s event, the Medscape Education team...

Medscape Education Global

- PMLiVE

AstraZeneca announces major expansion of Canadian research footprint

The investment includes the creation of 500 jobs and a new rare disease research hub

EU flag

European Commission grants AstraZeneca three new approvals

The indications are for adults with liver and lung cancers, and chronic lymphocytic leukaemia

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links